Clinical trials of atopaxar

TrialResults-center www.trialresultscenter.org

1 acute coronary syndrome

Trial	Treatments	Patients	Trials design and methods
atopaxar vs placebo			
LANCELOT ACS n=603 follow-up:	400-mg loading dose of atopaxar followed by a daily dose of 50 mg, 100 mg, or 200 mg for 12 weeks versus placebo	unstable-angina or non-STEMI patients	Parallel groups
J-LANCELOT , 2010 n=NA follow-up:	atopaxar at a loading dose of 400 mg followed by 50 mg per day, 100 mg per day, or 200 mg per day for 12 weeks versus atopaxar at a loading dose of 400 mg followed by placebo	patients with acute coronary syndrome (unstable angina and NSTEMI)	Parallel groups Japan

More details and results :

- antithrombotics for acute coronary syndrome in all type of patients at http://www.trialresultscenter.org/go-Q24
- antiplatelets drug for acute coronary syndrome in ACS (excluding AMI) at http://www.trialresultscenter.org/go-Q169
- antiplatelets drug for acute coronary syndrome in all type of patients at http://www.trialresultscenter.org/go-Q346

References

LANCELOT ACS, :

O'Donoghue ML, Bhatt DL, Wiviott SD, Goodman SG, Fitzgerald DJ, Angiolillo DJ, Goto S, Montalescot G, Zeymer U, Aylward PE, Guetta V, Dudek D, Ziecina R, Contant CF, Flather MD Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of ThrombinAcute Coronary Syndromes Trial. Circulation 2011 May 3;123:1843-53 [21502577] 10.1161/CIRCULATIONAHA.110.000786

J-LANCELOT, 2010: